enGenes Biotech GmbH

Founded

2014

Staff

9

Organization type

RDM biotech/pharma

Region

Vienna

Cluster

LISAvienna

Focus

industrial processing

Focus

consumables / reagents

enGenes Biotech develops customized solutions for the cost-effective production of recombinant proteins and plasmid DNA in microbial expression systems. The company’s unique, proprietary, E. coli-based enGenes-X-press technology platform achieves outstanding yields of soluble and active recombinant protein or plasmid DNA by reducing biological complexity. This is achieved by decoupling biomass growth from product formation.

R&D:enGenes Biotech offers patent-protected technology solutions and services for the microbial production of recombinant proteins and plasmid DNA. The X-press platform also offers i) secretion of proteins to the cell-free supernatant, ii) site-specific labeling of proteins by using non-canonical amino acids and iii) continuous manufacturing.

Production:enGenes expression products and services are highly relevant for companies with interest in developing cost-effective manufacturing processes for recombinant proteins. The world-leading X-press technology for growth-decoupled protein production allows enGenes to develop economic, scalable, and efficient production processes within short time frames to enhance the commercial success of unique products.

Services:* Feasibility studies *Process development (USP/DSP) * Process scale-up

Sales/Distribution:enGenes Biotech is producing, selling and distributing high-quality SARS CoV-2 antigens (Spike, RBD, and Nucleocapsid protein) that can be used for serological testing and IVD-applications.